These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 14638887)

  • 21. Cerebrospinal fluid hypocretin 1 deficiency, overweight, and metabolic dysregulation in patients with narcolepsy.
    Heier MS; Jansson TS; Gautvik KM
    J Clin Sleep Med; 2011 Dec; 7(6):653-8. PubMed ID: 22171205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiency.
    Andlauer O; Moore H; Jouhier L; Drake C; Peppard PE; Han F; Hong SC; Poli F; Plazzi G; O'Hara R; Haffen E; Roth T; Young T; Mignot E
    JAMA Neurol; 2013 Jul; 70(7):891-902. PubMed ID: 23649748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preliminary results on CSF biomarkers for hypothalamic dysfunction in Kleine-Levin syndrome.
    Lopez R; Barateau L; Chenini S; Dauvilliers Y
    Sleep Med; 2015 Jan; 16(1):194-6. PubMed ID: 25454350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions.
    Ripley B; Overeem S; Fujiki N; Nevsimalova S; Uchino M; Yesavage J; Di Monte D; Dohi K; Melberg A; Lammers GJ; Nishida Y; Roelandse FW; Hungs M; Mignot E; Nishino S
    Neurology; 2001 Dec; 57(12):2253-8. PubMed ID: 11756606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical neurophysiology of CNS hypersomnias.
    Barateau L; Lopez R; Dauvilliers Y
    Handb Clin Neurol; 2019; 161():353-367. PubMed ID: 31307613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness.
    Hong SC; Lin L; Jeong JH; Shin YK; Han JH; Lee JH; Lee SP; Zhang J; Einen M; Mignot E
    Sleep; 2006 Nov; 29(11):1429-38. PubMed ID: 17162989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HLA-DQB1 allele and hypocretin in Korean narcoleptics with cataplexy.
    Jeong JH; Hong SC; Shin YK; Han JH; Lee SP
    J Korean Med Sci; 2007 Feb; 22(1):127-31. PubMed ID: 17297265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on hypersomnias of central origin.
    Drakatos P; Leschziner GD
    Curr Opin Pulm Med; 2014 Nov; 20(6):572-80. PubMed ID: 25165990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy.
    Nishino S; Ripley B; Overeem S; Nevsimalova S; Lammers GJ; Vankova J; Okun M; Rogers W; Brooks S; Mignot E
    Ann Neurol; 2001 Sep; 50(3):381-8. PubMed ID: 11558795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miRNA profiles in plasma from patients with sleep disorders reveal dysregulation of miRNAs in narcolepsy and other central hypersomnias.
    Holm A; Bang-Berthelsen CH; Knudsen S; Kornum BR; Modvig S; Jennum P; Gammeltoft S
    Sleep; 2014 Sep; 37(9):1525-33. PubMed ID: 25142559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Narcolepsy and Other Central Hypersomnias.
    Dauvilliers Y; Barateau L
    Continuum (Minneap Minn); 2017 Aug; 23(4, Sleep Neurology):989-1004. PubMed ID: 28777172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HLA DQB1*06:02 negative narcolepsy with hypocretin/orexin deficiency.
    Han F; Lin L; Schormair B; Pizza F; Plazzi G; Ollila HM; Nevsimalova S; Jennum P; Knudsen S; Winkelmann J; Coquillard C; Babrzadeh F; Strom TM; Wang C; Mindrinos M; Fernandez Vina M; Mignot E
    Sleep; 2014 Oct; 37(10):1601-8. PubMed ID: 25197808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSF hypocretin measures in patients with obstructive sleep apnea.
    Kanbayashi T; Inoue Y; Kawanishi K; Takasaki H; Aizawa R; Takahashi K; Ogawa Y; Abe M; Hishikawa Y; Shimizu T
    J Sleep Res; 2003 Dec; 12(4):339-41. PubMed ID: 14633246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased cerebrospinal fluid hypocretin-1 levels near the onset of narcolepsy in 2 prepubertal children.
    Kubota H; Kanbayashi T; Tanabe Y; Ito M; Takanashi J; Kohno Y; Shimizu T
    Sleep; 2003 Aug; 26(5):555-7. PubMed ID: 12938807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cataplexy with Normal Sleep Studies and Normal CSF Hypocretin: An Explanation?
    Drakatos P; Leschziner G
    J Clin Sleep Med; 2016 Mar; 12(3):449-50. PubMed ID: 26564387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Undetectable CSF level of orexin A (hypocretin-1) in a HLA-DR2 negative patient with narcolepsy-cataplexy.
    Dalal MA; Schuld A; Pollmächer T
    J Sleep Res; 2002 Sep; 11(3):273. PubMed ID: 12220324
    [No Abstract]   [Full Text] [Related]  

  • 37. Idiopathic hypersomnia and Kleine-Levin syndrome.
    Arnulf I; Dodet P; Leu-Semenescu S; Maranci JB
    Rev Neurol (Paris); 2023 Oct; 179(7):741-754. PubMed ID: 37684104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monozygotic twins concordant for narcolepsy-cataplexy without any detectable abnormality in the hypocretin (orexin) pathway.
    Khatami R; Maret S; Werth E; Rétey J; Schmid D; Maly F; Tafti M; Bassetti CL
    Lancet; 2004 Apr; 363(9416):1199-200. PubMed ID: 15081654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Studies of humoral immunity to preprohypocretin in human leukocyte antigen DQB1*0602-positive narcoleptic subjects with cataplexy.
    Black JL; Silber MH; Krahn LE; Avula RK; Walker DL; Pankratz VS; Fredrickson PA; Slocumb NL
    Biol Psychiatry; 2005 Sep; 58(6):504-9. PubMed ID: 16043129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Undetectable levels of CSF hypocretin-1 (orexin-A) in two prepubertal boys with narcolepsy.
    Tsukamoto H; Ishikawa T; Fujii Y; Fukumizu M; Sugai K; Kanbayashi T
    Neuropediatrics; 2002 Feb; 33(1):51-2. PubMed ID: 11930279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.